Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, et al.
Annals of the Rheumatic Diseases (2016) Vol. 75, Iss. 6, pp. 1065-1073
Open Access | Times Cited: 260

Showing 1-25 of 260 citing articles:

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 829
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis Care & Research (2018) Vol. 71, Iss. 1, pp. 2-29
Open Access | Times Cited: 437
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 1, pp. 5-32
Open Access | Times Cited: 397
Psoriasis: Which therapy for which patient
Shivani B. Kaushik, Mark Lebwohl
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 27-40
Closed Access | Times Cited: 320
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
George S. Baillie, Gonzalo S. Tejeda, Michy P. Kelly
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 10, pp. 770-796
Open Access | Times Cited: 282
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo, Gary E. Myerson, Roy Fleischmann, et al.
The Journal of Rheumatology (2016) Vol. 43, Iss. 9, pp. 1724-1734
Closed Access | Times Cited: 198
Psoriatic arthritis
Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 192
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
Kristian Reich, Melinda Gooderham, L. Green, et al.
Journal of the European Academy of Dermatology and Venereology (2016) Vol. 31, Iss. 3, pp. 507-517
Open Access | Times Cited: 180
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 778-786
Open Access | Times Cited: 169
Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome
Gülen Hatemi, Alfred Mahr, Yoshiaki Ishigatsubo, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 20, pp. 1918-1928
Open Access | Times Cited: 166
New Therapeutics for Ulcerative Colitis
Robert Hirten, Bruce E. Sands
Annual Review of Medicine (2021) Vol. 72, Iss. 1, pp. 199-213
Closed Access | Times Cited: 107
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 70
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley, Diamant Thaçi, P. Joly, et al.
Journal of the American Academy of Dermatology (2017) Vol. 77, Iss. 2, pp. 310-317.e1
Open Access | Times Cited: 167
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
Gillian M. Keating
Drugs (2017) Vol. 77, Iss. 4, pp. 459-472
Closed Access | Times Cited: 166
Enthesitis: A hallmark of psoriatic arthritis
Gurjit S. Kaeley, Lihi Eder, Sibel Zehra Aydın, et al.
Seminars in Arthritis and Rheumatism (2018) Vol. 48, Iss. 1, pp. 35-43
Open Access | Times Cited: 159
Psoriatic arthritis
Vanessa Ocampo D, Dafna D. Gladman
F1000Research (2019) Vol. 8, pp. 1665-1665
Open Access | Times Cited: 143
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis
Eric Gracey, Lars Vereecke, Dermot McGovern, et al.
Nature Reviews Rheumatology (2020) Vol. 16, Iss. 8, pp. 415-433
Closed Access | Times Cited: 134
Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions
Lyn D. Ferguson, Stefan Siebert, Iain B. McInnes, et al.
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 8, pp. 461-474
Open Access | Times Cited: 126
Clinical management of psoriatic arthritis
Filip Van den Bosch, Laura C. Coates
The Lancet (2018) Vol. 391, Iss. 10136, pp. 2285-2294
Open Access | Times Cited: 120
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial
Allard R.J.V. Vossen, Martijn B. A. van Doorn, Hessel H. van der Zee, et al.
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 80-88
Closed Access | Times Cited: 115
Dactylitis: A hallmark of psoriatic arthritis
Gurjit S. Kaeley, Lihi Eder, Sibel Zehra Aydın, et al.
Seminars in Arthritis and Rheumatism (2018) Vol. 48, Iss. 2, pp. 263-273
Open Access | Times Cited: 113
Enthesitis: Much More Than Focal Insertion Point Inflammation
‬‬‬‬Abdulla Watad, Richard Cuthbert, Howard Amital, et al.
Current Rheumatology Reports (2018) Vol. 20, Iss. 7
Open Access | Times Cited: 104
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
Eric L. Simpson, Shinichi Imafuku, Yves Poulin, et al.
Journal of Investigative Dermatology (2018) Vol. 139, Iss. 5, pp. 1063-1072
Open Access | Times Cited: 103
The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
Yael Renert‐Yuval, Emma Guttman‐Yassky
Advances in Therapy (2017) Vol. 34, Iss. 7, pp. 1594-1609
Open Access | Times Cited: 95
Page 1 - Next Page

Scroll to top